Previous work by us and other groups have shown that losartan can ameliorate the manifestation of muscle disease in mouse models of DMD, MDC1A, Marfan syndrome and sarcopenia, likely by attenuating the pro-fibrotic action of TGF-β signalling [10,13,16,30,31]. Here, TGFB1 is linked to sarcopenia.